Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable
Journal of Law, Medicine & Ethics · 2024
DOI: 10.1017/jme.2024.56 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, 2024. Verfasst von Catherine S Hwang und 2 weiteren Autor:innen. Beteiligte Einrichtung: DIVISION OF PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS, DEPARTMENT OF MEDICINE, BRIGHAM AND WOMEN'S HOSPITAL AND HARVARD MEDICAL SCHOOL, BOSTON, MA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Drug Costs, Medicare. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Gefördert von: Arnold Ventures, HRSA HHS.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists are effective for treating obesity, but the high cost of these medications endangers the financial viability of our health care system. To ensure that these drugs are available to Medicare beneficiaries, pharmaceutical manufacturers must lower their prices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DIVISION OF PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS, DEPARTMENT OF MEDICINE, BRIGHAM AND WOMEN'S HOSPITAL AND HARVARD MEDICAL SCHOOL, BOSTON, MA.
ORCID-Profile: Catherine S Hwang, Benjamin N Rome
Förderung
- Arnold Ventures
- HRSA HHS
Zitieren
APA
Hwang, C. S., Kesselheim, A. S., & Rome, B. N. (2024). Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable. Journal of Law, Medicine & Ethics. https://doi.org/10.1017/jme.2024.56
Vancouver
Hwang CS, Kesselheim AS, Rome BN. Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable. Journal of Law, Medicine & Ethics. 2024. doi:10.1017/jme.2024.56
BibTeX
@article{Hwang2024,
author = {Hwang, Catherine S and Kesselheim, Aaron S and Rome, Benjamin N},
title = {Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable},
journal = {Journal of Law, Medicine & Ethics},
year = {2024},
doi = {10.1017/jme.2024.56}
}
EUVIMED